Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Triple-Drug hair loss treatment enters final testing phase

NCT ID NCT07435012

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a new topical solution called TH07 for male pattern baldness. It combines three active ingredients (minoxidil, finasteride, and latanoprost) to see if it grows more hair than standard minoxidil or a placebo. 420 men aged 18-49 with moderate hair loss will apply the treatment daily for 24 weeks, and hair growth will be measured using special photography.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TH07 (a combination of minoxidil, finasteride, and latanoprost)
What this could lead to
If successful, TH07 could offer a more effective topical treatment for male pattern baldness, potentially increasing hair count and thickness better than current options.
What could go wrong
This is a Phase 3 trial, but results may not show a significant advantage over existing treatments. Side effects from the drug combination are possible, and individual results vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 420 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 49 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males, 18 to 49 years of age on the date of enrollment. * Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale. * Body Mass Index (BMI) in the range of 19 to 35 kg/m2. * Not administered any systemic or topical treatment for AGA during the last 90 days. * Willing to comply with the following restrictions for the duration of trial participation: 1. Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA. 2. Hair dyes, hair texturizers, relaxers etc. 3. Any new vitamins or nutritional supplements that are currently not being administered. 4. Tattooing in the trial target area. 5. Blood donations. 6. OTC hair restorers. 7. Do not expose your pregnant partner to your hands/skin where the drug might be present. 8. Participation in any other drug or device trials during the course of this trial. Note: However, the following shall be permissible: 9. Non-medicated \& anti-dandruff shampoos, scalp/hair applications including styling gels, sprays, mousse (styling gels, sprays, mousse etc. not to be used on the days of trial visits to the clinic. 10. Current regimen (if any) of vitamins and nutritional supplements. * Willing and able to provide written informed consent for participation in the trial and to comply with all trial requirements. * Availability of and usage familiarity with a personal mobile phone (Android or iOS) with internet connectivity and a personal email address. Exclusion Criteria: * History of scalp treatment including though not limited to any of the following: 1. Hair transplant or extension surgery. 2. Hair weaving. 3. Laser or light therapy on the scalp in the last 6 months. 4. Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months. 5-Any other surgical treatment for hair loss * Any of the following hair styles: 1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs. * Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial. * Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results. * History or likelihood of use of any of the specified medicines. * History or clinical diagnosis of any of the specified medical conditions. * Participation in any investigational or marketed drug or device trial in the last 90 days prior to screening for this trial. * Any other condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • YVR Aesthetic Training and Study Centre.

    RECRUITING

    Vancouver, British Columbia, V5Z1H2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.